Connect with us

Hi, what are you looking for?

Rare Neurodegenerative Diseases Market will Witness Steady Growth through 2030, Use of Plant Polyphenols to Gain Traction; Fact.MR

Key market players are constantly focusing on achieving accurate results and functional improvement.

ROCKVILLE, MD / ACCESSWIRE / October 28, 2020 / The global rare neurodegenerative disease treatment market is projected to surpass a valuation of US$ 116 billion by 2030, according to a new study by Fact.MR. Medical technology advancements offer consistent and better results, thereby, acting as a priority in the healthcare sector. This has projected as a major growth aspect for the market.

"Regular functioning and use of plant polyphenol aids neurotransmitter regulation. Increased research investment and developed medical assistance are anticipated to complement overall market growth," says a Fact.MR analyst.

Request a report sample to gain comprehensive market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=5197

Rare Neurodegenerative Disease Treatment Market – Key Takeaways

  • Hospital Pharmacies will account for the highest market share owing to rising demand by researchers and doctors.
  • Due to reduced levels of toxicity, neuroprotective agents are estimated to account for larger market share.
  • North America will continue to hold largest share in neurodegenerative disease treatment market.
  • Antioxidant benefits in plant polyphenol will widen the scope of therapeutic applications.

Rare Neurodegenerative Disease Treatment Market – Drivers

  • Steady government support and improved reimbursement policies pertaining to the medical industry
  • Advancements in medical technology for treatment and diagnosis.
  • Increasing cases of neurodegenerative diseases in North America and Europe.
  • Increased research, development and investments by leading manufactures.

Rare Neurodegenerative Disease Treatment Market – Constraints

  • High-priced nature of treatment can limit adoption over the forecast period.
  • Absence of trained professionals in developing economies will act as a major constraint in the market.

Impact of COVID-19 on Rare Neurodegenerative disease Treatment Market

COVID-19 had an adverse effect on worldwide businesses. According to new research, patients suffering from multiple sclerosis are at higher risk as symptoms are not easily visible. According to Chicago based Medicine Health System, 82% of patients' in America while 1 in 3 patients in Europe recorded neurological symptoms post COVID treatment but redirection of medical resources towards coronavirus treatment and strict restrictions will reduce the adoption of neurological treatments.

Explore the Rare Neurodegenerative Disease Treatment market comprising of 78 figures and 30 data tables, along with the table of contents. You can find a detailed market segmentation on https://www.factmr.com/report/5197/rare-neurodegenerative-disease-treatment-market

Rare Neurodegenerative Market – Competition Landscape

Leading players identified in the global market include Allergan Plc, Bayer AG, F.Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. Manufacturers are focussing on product launches and improvements in functionality. For instance, PTC Therapeutics launched PTC Pinpoint, which is a genetic testing program to detect neurotransmitter disorders.

More on the Report

The Fact.MR's market research report provides in-depth insights into the rare neurodegenerative disease treatment market. The market is scrutinized on the basis of indication (autism, migraine, narcolepsy, sclerosis etc.), drug class (neurotransmitter agent, neuroprotective agent, biologics etc.) and across major regions (North America, Europe, East Asia, South Asia, Latin America, and Middle East & Africa (MEA).

Explore Wide-ranging Coverage of Fact.MR's Healthcare Landscape

Diabetic Neuropathy Market Find insights on the market with analysis of segments, statistics, influencers, market players, and business strategies adopted over the forecast period of 2020 to 2025.

Neurointerventional Devices Market Fact.MR's report on the ultra-wide field imaging device market offers insights on the market during 2017-2022, including restraints, revenue sources, market leaders, and market strategies.

Diagnostic Imaging Services Market: Read an analysis of the diagnostic imaging services market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. Fact.MR's latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: [email protected]
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1681/global-rare-neurodegenerative-disease-treatment-market

SOURCE: Fact.MR

View source version on accesswire.com:
https://www.accesswire.com/612744/Rare-Neurodegenerative-Diseases-Market-will-Witness-Steady-Growth-through-2030-Use-of-Plant-Polyphenols-to-Gain-Traction-FactMR

AccessWire
Written By

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.

You may also like:

World

Calling for urgent action is the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF)

Business

The cathedral is on track to reopen on December 8 - Copyright AFP Ludovic MARINParis’s Notre-Dame Cathedral, ravaged by fire in 2019, is on...

Business

Saudi Aramco President & CEO Amin Nasser speaks during the CERAWeek oil summit in Houston, Texas - Copyright AFP Mark FelixPointing to the still...

Business

Hyundai on Wednesday revealed plans to invest more than $50 billion in South Korea by 2026.